Halberd Corporation (HALB)
USD 0.0
(-8.33%)
USD 0.0
(-8.33%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 | -208.00 USD | -115.76% |
| 2023 | 1320.00 USD | -83.09% |
| 2022 | 7806.00 USD | 727.78% |
| 2021 | 943.00 USD | 0.0% |
| 2020 | - USD | 0.0% |
| 2019 | - USD | 0.0% |
| 2018 | - USD | -100.0% |
| 2017 | 151.22 Thousand USD | -8.06% |
| 2016 | 164.48 Thousand USD | 0.0% |
| 2008 | 6369.00 USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q3 | -257.00 USD | -220.66% |
| 2024 Q4 | - USD | 100.0% |
| 2024 Q2 | 213.00 USD | 229.88% |
| 2024 Q1 | -164.00 USD | -223.31% |
| 2023 Q3 | 135.00 USD | 158.44% |
| 2023 Q4 | 133.00 USD | -1.48% |
| 2023 Q1 | 256.00 USD | -86.39% |
| 2023 FY | 1320.00 USD | -83.09% |
| 2023 Q2 | -231.00 USD | -190.23% |
| 2022 Q4 | 1881.00 USD | 82.62% |
| 2022 Q3 | 1030.00 USD | 4.89% |
| 2022 Q2 | 982.00 USD | -71.17% |
| 2022 FY | 7806.00 USD | 727.78% |
| 2022 Q1 | 3406.00 USD | 572.4% |
| 2021 Q4 | -721.00 USD | 21.97% |
| 2021 FY | 943.00 USD | 0.0% |
| 2021 Q3 | -924.00 USD | -160.83% |
| 2021 Q2 | 1519.00 USD | 0.0% |
| 2021 Q1 | 1519.00 USD | 0.0% |
| 2020 FY | - USD | 0.0% |
| 2019 FY | - USD | 0.0% |
| 2018 FY | - USD | -100.0% |
| 2017 FY | 151.22 Thousand USD | -8.06% |
| 2016 FY | 164.48 Thousand USD | 0.0% |
| 2009 Q3 | 49.00 USD | -94.44% |
| 2009 Q2 | 881.00 USD | -73.29% |
| 2009 Q1 | 3299.00 USD | -34.56% |
| 2008 Q3 | 1328.00 USD | 0.0% |
| 2008 Q2 | - USD | 0.0% |
| 2008 FY | 6369.00 USD | 0.0% |
| 2008 Q1 | - USD | 0.0% |
| 2008 Q4 | 5041.00 USD | 279.59% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Arch Therapeutics, Inc. | -2439.00 USD | 91.472% |
| Evofem Biosciences, Inc. | 11.7 Million USD | 100.002% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | 99.935% |
| Rebus Holdings, Inc. | - USD | Infinity% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | 100.0% |
| Qrons Inc. | - USD | Infinity% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 99.999% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | 99.569% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | 99.833% |
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | 100.001% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | 106.705% |
| Institute of Biomedical Research Corp. | - USD | Infinity% |
| SQZ Biotechnologies Company | 9.79 Million USD | 100.002% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | 100.316% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | 99.391% |
| Mesoblast Limited | -35.16 Million USD | 99.999% |
| Marizyme, Inc. | 457.7 Thousand USD | 100.045% |
| Genus plc | 178.7 Million USD | 100.0% |
| VioQuest Pharmaceuticals, Inc. | - USD | Infinity% |
| Pharming Group N.V. | 220.1 Million USD | 100.0% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | 100.334% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | 100.051% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | 98.109% |
| ContraFect Corporation | -154 Thousand USD | 99.865% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | 99.584% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | 100.271% |
| IMV Inc. | -962.29 Thousand USD | 99.978% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | 99.946% |
| MultiCell Technologies, Inc. | 49.32 USD | 521.736% |
| ONE Bio Corp. | 20.12 Million USD | 100.001% |
| Accustem Sciences Inc. | - USD | Infinity% |
| RVL Pharmaceuticals plc | 40.26 Million USD | 100.001% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | 48.9 Thousand USD | 100.425% |
| Q BioMed Inc. | -8988.00 USD | 97.686% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | 100.001% |
| Mosaic ImmunoEngineering Inc. | - USD | Infinity% |
| Biomind Labs Inc. | -15.42 Thousand USD | 98.651% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | 100.0% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | 99.982% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | 100.297% |
| GlobeStar Therapeutics Corporation | - USD | Infinity% |
| THC Farmaceuticals, Inc. | -4952.00 USD | 95.8% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | 100.148% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | 99.787% |
| GB Sciences, Inc. | -624.00 USD | 66.667% |
| Alpha Cognition Inc. | -86.02 Thousand USD | 99.758% |
| HST Global, Inc. | - USD | Infinity% |
| CSL Limited | 7.56 Billion USD | 100.0% |
| Wesana Health Holdings Inc. | - USD | Infinity% |
| Enzolytics Inc. | 30.7 Thousand USD | 100.677% |
| Agentix Corp. | - USD | Infinity% |
| Resverlogix Corp. | - USD | Infinity% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | 100.043% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | 1.1 Billion USD | 100.0% |
| Enzon Pharmaceuticals, Inc. | - USD | Infinity% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | 99.96% |
| RespireRx Pharmaceuticals Inc. | - USD | Infinity% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | 100.034% |
| Zenith Capital Corp. | - USD | Infinity% |
| Genscript Biotech Corporation | 409.55 Million USD | 100.0% |
| Ember Therapeutics, Inc. | - USD | Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | 97.651% |
| WPD Pharmaceuticals Inc. | - USD | Infinity% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | 99.752% |
| Kadimastem Ltd | -630.13 Thousand USD | 99.967% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | 100.021% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | 9.61 Million USD | 100.002% |
| BioStem Technologies, Inc. | 15.42 Million USD | 100.001% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | - USD | Infinity% |
| LadRx Corporation | -11.83 Thousand USD | 98.243% |
| Cell Source, Inc. | - USD | Infinity% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | 100.118% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | 100.118% |
| NovAccess Global Inc. | - USD | Infinity% |
| Affymax, Inc. | 1.35 Million USD | 100.015% |
| Itoco Inc. | - USD | Infinity% |
| Rasna Therapeutics, Inc. | - USD | Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | Infinity% |
| Mobile Lads Corp. | - USD | Infinity% |
| CytoDyn Inc. | -29 Thousand USD | 99.283% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | - USD | Infinity% |
| NanoSphere Health Sciences Inc. | - USD | Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | 100.046% |
| SYBLEU INC | 11.69 Thousand USD | 101.778% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | 100.005% |
| Bioxytran, Inc. | -8285.00 USD | 97.489% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | - USD | Infinity% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | - USD | Infinity% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | - USD | Infinity% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | - USD | Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | 99.944% |
| Neutra Corp. | 14.33 Thousand USD | 101.451% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | 99.746% |
| PureTech Health plc | -1.6 Million USD | 99.987% |
| Coeptis Therapeutics, Inc. | -1 Million USD | 99.979% |
| IXICO plc | 3.27 Million USD | 100.006% |
| IntelGenx Technologies Corp. | -694 Thousand USD | 99.97% |
| Gelesis Holdings, Inc. | -1.79 Million USD | 99.988% |
| CSL Limited | 7.7 Billion USD | 100.0% |
| Cellectis S.A. | 18 Thousand USD | 101.156% |